BioDelivery Sciences International Inc
NASDAQ:BDSI
BioDelivery Sciences International Inc
Revenue
BioDelivery Sciences International Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
BioDelivery Sciences International Inc
NASDAQ:BDSI
|
Revenue
$166.7m
|
CAGR 3-Years
44%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
BioDelivery Sciences International Inc
Revenue Breakdown
Breakdown by Geography
BioDelivery Sciences International Inc
Breakdown by Segments
BioDelivery Sciences International Inc
Total Revenue:
166.7m
USD
|
Product Sales, Net:
164.6m
USD
|
Belbuca:
148.2m
USD
|
Symproic:
16.4m
USD
|
Product Royalty Revenues:
2.1m
USD
|
See Also
What is BioDelivery Sciences International Inc's Revenue?
Revenue
166.7m
USD
Based on the financial report for Dec 31, 2021, BioDelivery Sciences International Inc's Revenue amounts to 166.7m USD.
What is BioDelivery Sciences International Inc's Revenue growth rate?
Revenue CAGR 5Y
61%
Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for BioDelivery Sciences International Inc have been 44% over the past three years , 61% over the past five years .